Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds
Regeneron Pharmaceutical Inc.’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted their own antibody response, a large-scale study in the U.K. published on Wednesday found.